Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 17 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-5.93 Insider Own13.56% Shs Outstand68.00M Perf Week3.94%
Market Cap2.24B Forward P/E- EPS next Y-4.66 Insider Trans-0.11% Shs Float59.15M Perf Month-4.70%
Income-354.80M PEG- EPS next Q-1.12 Inst Own94.96% Short Float14.64% Perf Quarter-37.53%
Sales71.30M P/S31.36 EPS this Y39.01% Inst Trans-1.07% Short Ratio11.79 Perf Half Y60.99%
Book/sh8.93 P/B3.66 EPS next Y-15.48% ROA-29.71% Short Interest8.66M Perf Year40.86%
Cash/sh17.17 P/C1.90 EPS next 5Y- ROE-63.32% 52W Range13.57 - 53.08 Perf YTD-20.60%
Dividend Est.- P/FCF- EPS past 5Y23.62% ROI-58.09% 52W High-38.43% Beta1.97
Dividend TTM- Quick Ratio4.94 Sales past 5Y80.30% Gross Margin90.60% 52W Low140.83% ATR (14)1.77
Dividend Ex-Date- Current Ratio4.94 EPS Y/Y TTM-4.89% Oper. Margin-556.94% RSI (14)43.95 Volatility5.52% 4.92%
Employees445 Debt/Eq0.00 Sales Y/Y TTM-46.03% Profit Margin-497.62% Recom1.25 Target Price68.44
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q37.01% Payout- Rel Volume0.73 Prev Close32.11
Sales Surprise-23.20% EPS Surprise31.68% Sales Q/Q-22.15% EarningsMay 07 BMO Avg Volume734.35K Price32.68
SMA200.36% SMA50-12.49% SMA2002.90% Trades Volume537,140 Change1.78%
Date Action Analyst Rating Change Price Target Change
Feb-28-24Reiterated Oppenheimer Outperform $95 → $80
Feb-14-24Downgrade Citigroup Buy → Neutral $36 → $55
Feb-01-24Initiated Goldman Buy $70
Dec-19-23Upgrade Wells Fargo Equal Weight → Overweight $25 → $63
Dec-06-23Upgrade Jefferies Hold → Buy $40
Nov-20-23Upgrade Guggenheim Neutral → Buy
Oct-23-23Upgrade Wedbush Neutral → Outperform $27 → $24
Jun-26-23Resumed Oppenheimer Outperform $95
Jan-12-23Downgrade Guggenheim Buy → Neutral
Jan-03-23Downgrade Wells Fargo Overweight → Equal Weight $83 → $49
May-16-24 09:10AM
May-09-24 04:42PM
08:36AM Loading…
May-08-24 08:36AM
May-07-24 01:54PM
May-02-24 10:00AM
May-01-24 12:00PM
Apr-30-24 10:30AM
Apr-26-24 10:00AM
04:30PM Loading…
Apr-24-24 04:30PM
Apr-11-24 04:19PM
Apr-09-24 08:48AM
Mar-18-24 04:40PM
Mar-04-24 07:00AM
Feb-28-24 08:30AM
Feb-27-24 08:30AM
Feb-23-24 09:55AM
12:00PM Loading…
Feb-21-24 12:00PM
Feb-20-24 04:05PM
Feb-14-24 08:00AM
Feb-08-24 08:26AM
Feb-06-24 09:55AM
Feb-02-24 02:59AM
Feb-01-24 04:30PM
Jan-17-24 12:00PM
Jan-16-24 05:01PM
Jan-01-24 09:55AM
Dec-27-23 05:03AM
Dec-25-23 09:55AM
Dec-18-23 02:58PM
Dec-15-23 09:40AM
Dec-05-23 10:52PM
Dec-01-23 09:55AM
Nov-28-23 05:05PM
Nov-27-23 07:00AM
Nov-15-23 09:55AM
Nov-13-23 09:55AM
Nov-07-23 08:02AM
Nov-02-23 07:00AM
Oct-31-23 07:39AM
Oct-22-23 07:00AM
Oct-18-23 07:00AM
Oct-15-23 06:07PM
Sep-01-23 07:00AM
Aug-16-23 10:54AM
Aug-10-23 07:06AM
Aug-08-23 09:05AM
Jul-31-23 04:30PM
Jul-06-23 09:00AM
Jun-28-23 08:29PM
Jun-17-23 08:57AM
Jun-15-23 04:30PM
Jun-13-23 04:51AM
Jun-08-23 01:05PM
Jun-05-23 07:00AM
May-08-23 07:00AM
May-07-23 08:04AM
May-05-23 08:35AM
May-03-23 07:00AM
May-02-23 01:00PM
Apr-21-23 04:00PM
Apr-17-23 08:01AM
Apr-14-23 03:32AM
Apr-03-23 07:00AM
Feb-27-23 04:00PM
Feb-24-23 05:10AM
Feb-23-23 08:45AM
Feb-06-23 04:30PM
Jan-28-23 01:30PM
Jan-11-23 08:35AM
Jan-04-23 07:00AM
Jan-03-23 07:11AM
Dec-16-22 09:00AM
Nov-25-22 04:04AM
Nov-22-22 11:20AM
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Houston John GPresident and CEOFeb 23 '24Sale47.055,196244,4721,036,681Feb 27 06:35 PM
Cassidy Sean AChief Financial OfficerFeb 23 '24Sale47.051,70280,079181,916Feb 27 06:34 PM
Taylor IanChief Scientific OfficerFeb 23 '24Sale47.051,70180,032147,522Feb 27 06:33 PM
Peck RonaldChief Medical OfficerFeb 23 '24Sale47.051,69979,93867,516Feb 27 06:34 PM
Taylor IanChief Scientific OfficerJan 04 '24Option Exercise16.008,252132,032109,973Jan 08 04:39 PM
Peck RonaldChief Medical OfficerAug 11 '23Sale24.391,32432,28929,965Aug 14 05:27 PM